Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas Journal Article


Authors: Italiano, A.; Cioffi, A.; Penel, N.; Levra, M. G.; Delcambre, C.; Kalbacher, E.; Chevreau, C.; Bertucci, F.; Isambert, N.; Blay, J. Y.; Bui, B.; Antonescu, C.; D'adamo, D. R.; Maki, R. G.; Keohan, M. L.
Article Title: Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Abstract: BACKGROUND: Data regarding the role of anthracyclines and taxanes as first-line treatments of metastatic angiosarcoma are limited. METHODS: Records of 117 metastatic angiosarcoma patients who were treated with either doxorubicin or weekly paclitaxel were reviewed. RESULTS: Seventy-five patients (64%) were treated with weekly paclitaxel and 42 (36%) with single-agent doxorubicin. Patients in the weekly paclitaxel group were older and more frequently had angiosarcomas arising from the skin. In the doxorubicin group, 34 patients were evaluable for response: 2 (6%) had complete response, 8 (23.5%) had partial response, 10 (29.5%) had stable disease, and 14 (41%) had progressive disease. In the weekly paclitaxel group, 68 patients were evaluable for response: 9 (13%) had complete response, 27 (40%) had partial response, 20 (29.5%) had stable disease, and 12 (17.5%) had progressive disease. Objective responses to weekly paclitaxel were more frequent in cutaneous angiosarcomas, whereas tumor location did not impact response to doxorubicin. Median progression-free survival (PFS) was 4.9 months (95% confidence interval [95% CI], 3.9-6.0 months). Median overall survival (OS) was 8.5 months (95% CI, 6.4-10.7 months). On multivariate analysis, ECOG performance status (PS) was the sole independent factor associated with PFS and OS. CONCLUSIONS: First-line single-agent doxorubicin and weekly paclitaxel seem to have similar efficacy in metastatic angiosarcomas. Cutaneous angiosarcomas respond favorably to weekly paclitaxel. Best supportive care should be considered in patients with poor PS. © 2011 American Cancer Society.
Keywords: adult; cancer chemotherapy; controlled study; treatment response; aged; disease-free survival; retrospective studies; major clinical study; overall survival; neutropenia; bevacizumab; doxorubicin; cancer growth; drug efficacy; antineoplastic agents; gemcitabine; paclitaxel; chemotherapy; follow-up studies; progression free survival; skin neoplasms; angiosarcoma; hemangiosarcoma; retrospective study; drug fatality; patient care; medical record; sepsis; metastatic angiosarcoma
Journal Title: Cancer
Volume: 118
Issue: 13
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2012-07-01
Start Page: 3330
End Page: 3336
Language: English
DOI: 10.1002/cncr.26599
PROVIDER: scopus
PUBMED: 22045619
DOI/URL:
Notes: --- - "Export Date: 2 July 2012" - "CODEN: CANCA" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. David R D'Adamo
    37 D'Adamo
  2. Cristina R Antonescu
    619 Antonescu
  3. Robert Maki
    211 Maki
  4. Mary Louise Keohan
    66 Keohan
  5. Angela Cioffi
    8 Cioffi